Loading...

Novacyt S.A.

NVYTFPNK
HealthcareMedical - Devices
$0.54
$0.00(0.00%)

Novacyt S.A. (NVYTF) Company Profile & Overview

Explore Novacyt S.A.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Novacyt S.A. (NVYTF) Company Profile & Overview

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

SectorHealthcare
IndustryMedical - Devices
CEOMr. Lyn Dafydd Rees

Contact Information

33 1 39 46 51 04
13 Avenue Morane Saulnier, Le Vésinet, 78140

Company Facts

234 Employees
IPO DateJan 8, 2021
CountryFR
Actively Trading

Frequently Asked Questions